Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.
We reviewed the evidence in September 2017. We found nothing new that affects the recommendations in this guidance.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
May 2019: A simple discount patient access scheme for lenalidomide has replaced the previous complex scheme. This does not affect the cost effectiveness of lenalidomide. Contact HTA_UKandI@celgene.com for details.